The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a…
The largest trial review to date found no benefit of cannabinoids for anxiety and no randomised evidence for depression — is there any reason my case would be different from the people in those trials?
Top of the evidence hierarchy, independently funded. how we score evidence
One cannabidiol product is FDA-approved: Epidiolex (plant-derived purified CBD oral solution), indicated for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year and older.
The most recent systematic review and meta-analysis of randomised trials of cannabinoids as a primary treatment for mental disorders — 54 trials, 2,477 participants, searched to May 2025 — found no significant effect on anxiety outcomes and no randomised evidence at all for depression. Cannabinoids raised the odds of any adverse event (OR 1.75, 95% CI 1.25-2.46; number needed to harm 7) without raising serious adverse events, and the authors concluded that routine use of cannabinoids for mental disorders is currently rarely justified.
Worth asking
The largest trial review to date found no benefit of cannabinoids for anxiety and no randomised evidence for depression — is there any reason my case would be different from the people in those trials?
Source
The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. — Wilson J, Dobson O, Langcake A, et al. (2026)
Top-tier peer-reviewed journal
Read the source: https://doi.org/10.1016/S2215-0366(26)00015-5
DOI: 10.1016/S2215-0366(26)00015-5
How this was scored
- Study design
- Meta-analysis of randomised trials
- Funding
- Independently funded
- Published in
- Top-tier peer-reviewed journal
- Sample size
- 2,477
- Preregistered
- Yes
- Conflicts disclosed
- Yes
- Independent of proponent
- Yes
- Retracted
- No
Read the full scoring rubric, including what it can't tell you.
Published August 19, 2026.
Questions
How strong is the evidence behind this?
Resolv rates this source "gold standard". Top of the evidence hierarchy, independently funded. It scores 98 out of 100 on our published rubric. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.
What is the source for this?
The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. — Wilson J, Dobson O, Langcake A, et al. (2026). Published in: Top-tier peer-reviewed journal. DOI: 10.1016/S2215-0366(26)00015-5. The full source is linked on this page so you can read it yourself.
Who paid for this research, and does that matter?
Study design: Meta-analysis of randomised trials. Funding: Independently funded. The researchers were independent of whoever benefits from the result. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.
Is cannabidiol, cbd, hemp extract, cbd oil, epidiolex, full-spectrum hemp FDA approved for this use?
No. Its current status is: Not FDA-evaluated for this use. One cannabidiol product is FDA-approved: Epidiolex (plant-derived purified CBD oral solution), indicated for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year and older.
Is this medical advice?
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.